About the Authors
- William L. Redmond
-
* E-mail: william.redmond@providence.org
Affiliation Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, United States of America
- Todd Triplett
-
Affiliations Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, United States of America, Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
- Kevin Floyd
-
Affiliation Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, United States of America
- Andrew D. Weinberg
-
Affiliations Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, United States of America, Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon, United States of America
Competing Interests
ADW has patents pending for the use of OX40 agonists in patients with cancer and has an ownership interest in Agonox, LLC. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: WLR TT ADW. Performed the experiments: WLR TT KF. Analyzed the data: WLR TT KF ADW. Contributed reagents/materials/analysis tools: WLR TT ADW. Wrote the paper: WLR ADW.